Abstract
Purpose or Learning Objective Artificial intelligence (AI) with convolutional neural network allows fully automated detection and segmentation of bronchial changes on CT-scans of cystic fibrosis (CF). However, the superiority of two-dimensional (2D) versus three-dimensional (3D) architectures remains to be explored.
Method or Background CT-scans from fifty CF patients were retrospectively included at two CF reference centers. The nnUnet model was implemented in both 2D and 3D, and trained to segment five structural alterations: bronchiectasis, wall thickening, mucus plugs, bronchiolar impactions and consolidations. A semantic validation was done by using fifty CTs with a five-fold cross validation strategy, by comparing normalized Dice-Sorensen coefficient (DSC) between 2D and 3D architectures, with manual segmentations as Gold Standard.
Results or Findings The 3D nnUnet was found able to segment the five CF main hallmarks such as bronchiectasis, wall thickening, mucus plugs, bronchiolar impactions and consolidations. Metrics obtained with the 3D architecture were superior for mucus plugs, bronchiolar impactions and consolidations (p<0.001) but not significantly different for bronchiectasis and wall thickening (p>0.05).
Conclusion AI with the 3D-nnUnet model can perform fully automated segmentation of CF-related structural hallmarks on CT scans, and overcome 2D implementation. Non-invasive, holistic 3D quantifications are allowed for promising next clinical applications.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by RRI Impact
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All patients were provided written informed consent for reusing data from their medical records, after approval by the Ethic Committee of the University Hospital of Bordeaux (Full name Direction de la qualité et de la gestion des risques”; Affiliation: University Hospital of Bordeaux; study registration number : CHUBX2020RE0267).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Contact author: Pr. Gaël Dournes, Centre de Recherche Cardio-thoracique de Bordeaux, INSERM U1045, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France. Tel: +33 5 57 57 46 02 Fax: +33 5 57 57 16 95. E-mail: gael.dournes{at}chu-bordeaux.fr
After careful Review by the authors, it came out that the Supplemental File contained errors. We have uploaded a new version of the Supplemental files, to replace it. The main manuscript is, however, unchanged. Thank you.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
